SCHEMBL7410576

SCHEMBL7410576

O=C(NO)C(CNS(=O)(=O)c1cccc2ccccc12)NS(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP7 P09237 4/20 0.65
SLC6A9 P48067 6/20 0.51
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
ADAM17 P78536 1/20 0.50
MMP10 P09238 1/20 0.48
MMP9 P14780 1/20 0.48
NPY5R Q15761 2/20 0.47
HDAC1 Q13547 1/20 0.46
SCN1A P35498 2/20 0.46
SCN2A Q99250 2/20 0.46
SCN3A Q9NY46 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7410769 0.89 NPY5R (0.61) MMP7SLC6A9ADAM17MMP10MMP9
SCHEMBL7408520 0.89 MMP7 (0.53) MMP7SLC6A9SLC1A3SLC1A2SLC1A1
SCHEMBL7413636 0.89 MMP7 (0.53) MMP7SLC6A9MMP10MMP9NPY5R
SCHEMBL7417272 0.88 MMP7 (0.53) MMP7SLC6A9SLC1A3SLC1A2SLC1A1
SCHEMBL7418545 0.88 MMP7 (0.55) MMP7SLC6A9SLC1A3SLC1A2SLC1A1
SCHEMBL7417008 0.88 MMP7 (0.55) MMP7SLC6A9SLC1A3SLC1A2SLC1A1
SCHEMBL7419234 0.88 MMP7 (0.53) MMP7SLC6A9SLC1A3SLC1A2SLC1A1
SCHEMBL7411514 0.87 MMP7 (0.51) MMP7SLC6A9ADAM17MMP10MMP9
SCHEMBL7419448 0.87 MMP7 (0.58) MMP7SLC6A9ADAM17MMP10MMP9
SCHEMBL7411422 0.87 MMP7 (0.58) MMP7SLC6A9SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218389-B1 FOR THERAPY AND PROPHYLAXIS OF ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS; SKIN DISORDERS; OCULAR DISORDERS; INFLAMMATION AND GUM DISEASES, MULTIPLE SCLEROSIS, CACHEXIA, PREVENTING LOOSENING OF PROSTHETIC DEVICES THE PROCTER & GAMBLE CO. 2001-04-17 US disclosed
EP-1009737-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-06-21 EP disclosed
WO-1999006340-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1999-02-11 WO disclosed